TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18664347
Drug: Ambroxol hydrochloride
Normalized name: AMBROXOL HYDROCHLORIDE
DrugBank: Ambroxol (DB06742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambroxol hydrochloride injection (15 mg, twice daily for 10 days)
Study: 25632741
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (control group)
Study: 18664347
Drug: Tanreqing injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanreqing injection
Study: 18664347
Drug: Ambroxol hydrochloride
Normalized name: AMBROXOL HYDROCHLORIDE
DrugBank: Ambroxol (DB06742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambroxol hydrochloride injection
Study: 15856479
Drug: Daclizumab (DZB)
Normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daclizumab (DZB) induction and daily mycophenolate mofetil with steroids
Study: 15856479
Drug: Standard tacrolimus-based
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard tacrolimus-based triple therapy
Study: 1827074
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate 2 mg + 35 micrograms ethinyl estradiol
Study: 10543928
Drug: ramipril 5
Normalized name: ramipril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ramipril 5 mg/day
Study: 17763588
Drug: Midazolam dissolved
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam dissolved in glucose solution (n = 50)
Study: 17763588
Drug: Glucose solution
Normalized name: TrueControl Glucose Solution Level 0
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucose solution only with communication technique (n = 50)
Study: 15530676
Drug: Varicella vaccine
Normalized name: Varicella vaccine
DrugBank: Varicella zoster vaccine (live/attenuated) (DB10318)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varicella vaccine (Varilrix)
Study: 11354528
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of melatonin
Study: 9602585
Drug: Methoxamine 10
Normalized name: methoxamine
DrugBank: Methoxamine (DB00723)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methoxamine 10 mg i.m. (group MX)
Study: 9602585
Drug: 6% hetastarch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% hetastarch 500 ml and crystalloid 500 ml (group HS)
Study: 2275207
Drug: Rumalon-injections
Normalized name: Rumagon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rumalon-injections
Study: 29777234
Drug: Low dairy
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dairy products (≤600 mg calcium/day)
Study: 28127938
Drug: Crushed naloxegol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crushed naloxegol 25-mg tablets (suspended in water) administered orally
Study: 28127938
Drug: Crushed naloxegol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crushed naloxegol 25-mg tablets (suspended in water) administered by nasogastric tube
Study: 28127938
Drug: Naloxegol solution
DrugBank: Naloxegol (DB09049)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Naloxegol solution
Study: 28127938
Drug: Commercially available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available 25-mg tablet formulation
Study: 24549209
Drug: New method
Approvals — FDA: no, EMA: no, PMDA: no
Description: New method of suspension
Study: 24549209
Drug: Conventional suction
Normalized name: cetylpyridinium
DrugBank: Cetylpyridinium (DB11073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional suction suspension
Study: 19411357
Drug: Standard evidence-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard evidence-based treatment protocol
Study: 9744490
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate 320 mg
Study: 26035253
Drug: ABT-639 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-639 (100 mg oral dose)
Study: 9113633
Drug: High-AA diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-AA diet (1.5 g/d of additional 20:4n‐6)
Study: 9113633
Drug: Low-AA diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-AA diet (210 mg/d of 20:4n‐6)
Study: 8187319
Drug: rhIGF‐I administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIGF‐I administered subcutaneously in a dose of 40 micrograms/kg body weight
Study: 31148412
Drug: Rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10 mg administered in fasting state
Study: 31148412
Drug: Rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10 mg administered in fed state
Study: 19654233
Drug: PEG-GH (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-GH (1 mg for 3 weeks, then 2 mg for 3 weeks)
Study: 19654233
Drug: PEG-GH (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-GH (4 mg for 3 weeks, then 8 mg for 3 weeks)
Study: 19654233
Drug: PEG-GH (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-GH (4 mg for 6 weeks)
Study: 16966367
Drug: Capecitabine (1250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine (1250 mg/m(2) twice daily days 1-14) plus Docetaxel (75 mg/m(2) day 1)
Study: 16966367
Drug: Reduced doses
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced doses of Capecitabine (950 mg/m(2)) and Docetaxel (55 mg/m(2))
Study: 10670523
Drug: Electromotive drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electromotive drug administration of the 3-drug association orgotein-dexamethasone-lidocaine (study 1)
Study: 10670523
Drug: Electromotive drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electromotive drug administration of the 2-drug combination verapamil-dexamethasone (study 2)
Study: 9487787
Drug: Intercostal blocks
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intercostal blocks (ICB) with 5 ml bupivacaine 0.5%
Study: 9487787
Drug: Interpleural analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpleural analgesia (IPA) with 20 ml bupivacaine 0.25%
Study: 29469337
Drug: Praziquantel (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel (30 mg/(kg·d) for 2 days each year for three consecutive years)
Study: 29469337
Drug: Conventional liver
Normalized name: LIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional liver protection therapy and symptomatic treatment
Study: 20140619
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (7 days)
Study: 12739705
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg o.d.
Study: 16550734
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg b.i.d.
Study: 10561618
Drug: Intra-amniotic (15S)-15-methyl-prostaglandin
Normalized name: 15(S)-15-Methyl Prostaglandin F2α
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-amniotic (15S)-15-methyl-prostaglandin F2alpha (2.5 mg)
Study: 10561618
Drug: Intravaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravaginal misoprostol (200 microg, two doses at 12-hour intervals)
Study: 22421748
Drug: Adenovirus type
Normalized name: Adenovirus types 4 and 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenovirus type 5 (Ad5) vector‐based vaccine
Study: 12909491
Drug: Gonadotropin-releasing hormone
Normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gonadotropin-releasing hormone (GnRH) agonist treatment for 3 months before laparoscopic surgery
Study: 12909491
Drug: Endometriotic stromal
Normalized name: Allogeneic bone marrow-derived mesenchymal stromal cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endometriotic stromal cells obtained from patients with GnRH agonist treatment
Study: 6290132
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g guar gum with 25 g D-xylose
Study: 23435021
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (HT) - Daily conjugated equine estrogens (0.625 mg) and medroxyprogesterone acetate (2.5 mg; EPT) or conjugated equine estrogens (0.625 mg; ET)
Study: 15743112
Drug: Thioctic acid
Normalized name: Thioctic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thioctic acid at an oral dosage of 800 mg/day for 4 months
Study: 11064772
Drug: Oral cefuroxime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cefuroxime axetil for 10 days
Study: 11064772
Drug: Intramuscular benzathine
Normalized name: Cephapirin Benzathine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular benzathine penicillin (one dose)
Study: 8364872
Drug: LC9018 combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: LC9018 combined with radiation therapy
Study: 22310055
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy alone
Study: 21892418
Drug: Problem-solving treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-solving treatment (PST)
Study: 6397332
Drug: Spiramycin 500
Normalized name: spiramycin
DrugBank: Spiramycin (DB06145)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Spiramycin 500 mg 3-times daily for 3 days
Study: 6397332
Drug: Erythromycin 500
Normalized name: erythromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 500 mg 3-times daily for 5 days
Study: 30721586
Drug: Tolvaptan 15
Normalized name: tolvaptan 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan 15 mg + Furosemide 20 mg (TH group)
Study: 30721586
Drug: Tolvaptan 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan 7.5 mg + Furosemide 20 mg (TI group)
Study: 23163605
Drug: Negative-restrictive slogans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative-restrictive slogans (e.g., 'Don't drink')
Study: 15671112
Drug: hCG (10,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG (10,000 IU, single IM injection on day 19)
Study: 12025445
Drug: Iron therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron therapy for children with IDA after a 3-month follow-up period.
Study: 8600086
Drug: Sequential PCI
Normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential PCI
Study: 6179344
Drug: Oral retinoids
Normalized name: tocopheryl retinoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral retinoids in combination with bleomycin, cyclophosphamide, prednisone, and transfer factor
Study: 6179344
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no retinoids, only chemotherapy with bleomycin, cyclophosphamide, and prednisone)
Study: 11059999
Drug: Acute tryptophan
Normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute tryptophan depletion (induced by a 100 g amino acid drink following an overnight fast)
Study: 9114915
Drug: Orlistat (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat (80 mg) administered at mid-meal (group A)
Study: 9114915
Drug: Orlistat (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat (80 mg) administered 1 hour after mid-meal (group B)
Study: 9114915
Drug: Orlistat (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat (80 mg) administered 2 hours after mid-meal (group C)
Study: 363751
Drug: Aspirin 650
Normalized name: aspirin 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 650 mg
Study: 3540032
Drug: Ketorolac 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 5 mg
Study: 31594895
Drug: Reminders from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reminders from family members for adherence to antihypertensive medications.
Study: 31594895
Drug: Awareness of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Awareness of the names or purpose of their medications.
Study: 29467829
Drug: Best available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Best available non-surgical treatment (offloading cast applied for up to 12 weeks)
Study: 24041199
Drug: Standardized disorder-specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized disorder-specific Internet-based treatment (8 weeks)
Study: 9215092
Drug: Valaciclovir 500
Normalized name: valacyclovir 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valaciclovir 500 mg twice daily
Study: 19107321
Drug: Control foot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control foot (no treatment)
Study: 26539650
Drug: rosuvastatin 20
Normalized name: rosuvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 20 mg
Study: 26539650
Drug: atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: atorvastatin 10 mg
Study: 23728830
Drug: atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: atorvastatin 20 mg
Study: 15356085
Drug: Flutamide (62.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide (62.5 mg/d) plus metformin (850 mg/d) and ethinylestradiol-drospirenone (30 microg plus 3 mg, 21 d/month)
Study: 15356085
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (metformin (850 mg/d) and ethinylestradiol-drospirenone (30 microg plus 3 mg, 21 d/month) without flutamide
Study: 8162994
Drug: Prior inhalation
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior inhalation of a bronchodilator aerosol
Study: 31889152
Drug: Standard anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard anticoagulation (enoxaparin and warfarin, n=35)
Study: 23530484
Drug: Implantable cardioverter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implantable cardioverter defibrillator (ICD) therapy alone
Study: 15630143
Drug: Sodium citrate
Normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium citrate (0.5 g x kg(−1) body mass in 1.5 litres of solution)
Study: 17292647
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg codeine
Study: 18053632
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg naltrexone
Study: 9274760
Drug: Binocular visual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Binocular visual direction with adjacent binocular objects; specific intervention details such as dosage and duration are not available.
Study: 9274760
Drug: Monocular objects
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Monocular objects viewed in the presence of adjacent binocular objects; specific intervention details such as dosage and duration are not available.
Study: 9274760
Drug: Nonius lines
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonius lines as indicators of eye position; specific intervention details such as dosage and duration are not available.
Study: 1345049
Drug: Ketoprofen (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen (100 mg bid for 7 days)
Study: 3739581
Drug: Supplementary dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplementary dose of 20 ml mepivacaine 1% with adrenaline
Study: 3739581
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no supplementary dose)
Study: 25062713
Drug: Pitavastatin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin (2 mg/day)
Study: 16464810
Drug: Intensive pharmaceutical
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intensive pharmaceutical care campaign targeting inappropriate use of triptans
Study: 14725513
Drug: Esmolol (1mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (1mg x kg(‐1) bolus, followed by an infusion at 250 microg x kg(‐1)min(‐1))
Study: 11328905
Drug: Dalteparin (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin (initial dose reduced to 50% if no clotting observed, approximately 5000 IU IV)
Study: 30140582
Drug: Warfarin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin treatment
Study: 10495794
Drug: Cyclosporine alone
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine alone (monotherapy)
Study: 10495794
Drug: Cyclosporine plus
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine plus steroids (double therapy)
Study: 10495794
Drug: Cyclosporine plus
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine plus steroids plus azathioprine (triple therapy)
Study: 8607489
Drug: Double therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double therapy
Study: 31841577
Drug: Intravenous acyclovir,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous acyclovir, 5 mg/kg, 3 times daily for 14 days
Study: 25082852
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional preparation (Group 1)
Study: 25082852
Drug: Commercial high-fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial high-fat solution containing 43.8 g of lipids (Group 2)
Study: 25082852
Drug: 50 mL
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mL of olive oil (Group 3)
Study: 18480694
Drug: Mecamylamine hydrochloride
Normalized name: Mecamylamine Hydrochloride
DrugBank: Mecamylamine (DB00657)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mecamylamine hydrochloride (MEC) up to 10 mg/d; n = 11
Study: 11210400
Drug: Oxybutynin XL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin XL 15 mg (fed treatment)
Study: 29667290
Drug: Metformin 850
Normalized name: metFORMIN 850 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 850 mg thrice daily for 52 months
Study: 10150183
Drug: Trapidil (T)
Normalized name: trapidil
DrugBank: Trapidil (DB09283)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trapidil (T) 100 mg t.i.d.
Study: 10150183
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) 100 mg t.i.d.
Study: 27929203
Drug: Prasugrel (0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (0.08 mg/kg/day)
Study: 7601080
Drug: 200mg oral
Normalized name: AVANAFIL 200MG ORAL TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg oral iodized oil
Study: 7601080
Drug: 400mg oral
Normalized name: Mesna 400mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400mg oral iodized oil
Study: 28531241
Drug: Pravastatin sodium
Normalized name: Pravastatin Sodium
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pravastatin sodium (40 mg/d)
Study: 23634822
Drug: Vaccine (CAF01-adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine (CAF01-adjuvanted HIV-1 peptides)
Study: 17614012
Drug: Agonist and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agonist and antagonist activity during MVC
Study: 20191713
Drug: Experimental treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental treatments
Study: 9181163
Drug: Sequestration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequestration of one unit of fresh autologous blood (5-8 ml/kg); Group I
Study: 9181163
Drug: Sequestration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequestration of two units of fresh autologous blood (12-15 ml/kg); Group II
Study: 21619701
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) injections at a pharmacologic dose of 0.3 mg/kg/week
Study: 19003734
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg vitamin C supplementation
Study: 16816926
Drug: Ospemifene 90
Normalized name: Ospemifene
DrugBank: Ospemifene (DB04938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ospemifene 90 mg
Study: 12443837
Drug: Ospemifene (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ospemifene (all doses)
Study: 11740194
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (PRO-PRE)
Study: 9757959
Drug: Intramuscular methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular methotrexate 50 mg/m2
Study: 9757959
Drug: Intramuscular methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular methotrexate 60 mg/m2
Study: 9757959
Drug: Intramuscular methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular methotrexate (both dosages)
Study: 3145557
Drug: thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: thrombolytic therapy (overall)
Study: 28401417
Drug: Conventional oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oral education (control group)
Study: 1963015
Drug: Enoxaparin 40
Normalized name: ENOXAPARIN 40MG/0.4ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40 mg/day
Study: 19738135
Drug: Soluble intercellular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble intercellular adhesion molecule-1
Study: 16831981
Drug: Soluble interleukin-1
Normalized name: interleukin-1, beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble interleukin-1 receptor antagonist
Study: 9590863
Drug: Diamox administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diamox administered preoperatively
Study: 9590863
Drug: Mannitol or
Normalized name: mannitol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannitol or no drugs administered preoperatively
Study: 7075651
Drug: Sotalol 320
Normalized name: sotalol 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol 320 mg once daily